Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Return on Assets: 2022-2025

Historic Return on Assets for ARS Pharmaceuticals (SPRY) over the last 3 years, with Sep 2025 value amounting to -0.26%.

  • ARS Pharmaceuticals' Return on Assets rose 1.00% to -0.26% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.26%, marking a year-over-year increase of 1.00%. This contributed to the annual value of 0.03% for FY2024, which is 24.00% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Return on Assets stood at -0.26%, which was down 42.85% from -0.19% recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year Return on Assets high stood at -0.01% for Q4 2024, and its period low was -0.29% during Q3 2023.
  • Its 3-year average for Return on Assets is -0.21%, with a median of -0.25% in 2024.
  • In the last 5 years, ARS Pharmaceuticals' Return on Assets dropped by 15bps in 2023 and then rose by 27bps in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' Return on Assets (Quarterly) stood at -0.13% in 2022, then fell by 15bps to -0.28% in 2023, then climbed by 27bps to -0.01% in 2024, then grew by 1bps to -0.26% in 2025.
  • Its Return on Assets was -0.26% in Q3 2025, compared to -0.19% in Q2 2025 and -0.08% in Q1 2025.